Konstantinos Karamouzis
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Konstantinos Karamouzis has a total of 17 co-authors. Here are the top co-authors by number of shared publications:
- Ioannis Ntanasis-Stathopoulos
Department of Clinical Therapeutics, National and Kapodistrian University of Athens, 11528 Athens, Greece
3 shared publications - Maria Gavriatopoulou
Department of Clinical Therapeutics, National and Kapodistrian University of Athens, 11528 Athens, Greece
2 shared publications - Meletios Athanassios Dimopoulos
Department of Clinical Therapeutics, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece
2 shared publications Charalampos Filippatos
Department of Clinical Therapeutics School of Medicine, National and Kapodistrian University of Athens Athens Greece
1 shared publication- Efstathios Kastritis
Department of Clinical Therapeutics, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece
1 shared publication Evangelos Terpos
Department of Clinical Therapeutics School of Medicine, National and Kapodistrian University of Athens Athens Greece
1 shared publication
Latest Publications
- Open Access
Small Extracellular Vesicle-Associated microRNA in Cancer: Biology and Applications in Translational Research and Precision Oncology
Small extracellular vesicles (sEVs) are extracellular vesicles that mediate intercellular communication through the transfer of bioactive molecules, including proteins, lipids, and nucleic acids. Among their cargo, microRNAs (miRNAs) have emerged as critical regulators of gene expression with significant implications in cancer biology. Tumor-derived extracellular vesicle-associated microRNAs (EV-miRNAs) can reprogram recipient cells, promoting oncogenesis, metastasis, angiogenesis, and therapeutic resistance. This review provides a comprehensive overview of EV-miRNAs in cancer, examining their biogenesis, mechanisms of intercellular transfer, and functional roles in tumor progression. We discuss the clinical potential of EV-miRNAs as non-invasive biomarkers for cancer diagnosis and prognosis, as well as their emerging applications in targeted therapeutic strategies. Furthermore, we address current challenges related to isolation techniques, quantification methods, and standardization protocols that hinder clinical translation. Finally, we outline future directions for integrating EV-miRNA analysis into precision oncology frameworks and liquid biopsy platforms, highlighting opportunities to advance personalized cancer care.
Open AccessSmall Extracellular Vesicle-Associated microRNA in Cancer: Biology and Applications in Translational Research and Precision Oncology
Small extracellular vesicles (sEVs) are extracellular vesicles that mediate intercellular communication through the transfer of bioactive molecules, including proteins, lipids, and nucleic acids. Among their cargo, microRNAs (miRNAs) have emerged as critical regulators of gene expression with significant implications in cancer biology. Tumor-derived extracellular vesicle-associated microRNAs (EV-miRNAs) can reprogram recipient cells, promoting oncogenesis, metastasis, angiogenesis, and therapeutic resistance. This review provides a comprehensive overview of EV-miRNAs in cancer, examining their biogenesis, mechanisms of intercellular transfer, and functional roles in tumor progression. We discuss the clinical potential of EV-miRNAs as non-invasive biomarkers for cancer diagnosis and prognosis, as well as their emerging applications in targeted therapeutic strategies. Furthermore, we address current challenges related to isolation techniques, quantification methods, and standardization protocols that hinder clinical translation. Finally, we outline future directions for integrating EV-miRNA analysis into precision oncology frameworks and liquid biopsy platforms, highlighting opportunities to advance personalized cancer care.
- Open Access
- 2 April 2026
- Published by Wiley in American Journal of Hematology
- Vol. 101 (7) , 1484-1493
The Role of Bispecific Antibodies in Relapsed/Refractory Multiple Myeloma With Renal Impairment: A Systematic Review
Renal impairment (RI), defined as estimated glomerular filtration rate less than 60 mL/min with or without the need for dialysis, is a frequent and severe complication in patients with relapsed/refractory multiple myeloma (RRMM), as it can affect patient prognosis, drug metabolism and treatment options. Although bispecific antibodies (BsAbs) have been approved in RRMM patients, their safety and efficacy in patients with RI remain insufficiently characterized, as most clinical trials excluded individuals with significant renal dysfunction. This systematic review was conducted in accordance with the PRISMA guidelines. PubMed, Scopus, and ScienceDirect were searched up to February 2, 2026, for clinical trials and retrospective real‐world studies evaluating BsAbs in RRMM patients with reported data from patients with RI. Abstracts presented in major international scientific congresses over the preceding 3 years, including ASH, IMS, ASCO, EHA, EMN, were also systematically screened. A total of 11 eligible studies were identified, including 3 pivotal trials and 8 real‐world cohorts, encompassing 1117 patients. ORR, PFS and OS were comparable between patients with and without RI. Safety profile, including incidence of cytokine release syndrome (CRS), immune effector cell‐associated neurotoxicity (ICANS), infections and hematologic toxicities were also comparable across renal subgroups. Only the incidence of thrombocytopenia was significantly increased in patients with RI. Overall, BsAbs demonstrate substantial efficacy and manageable safety in RRMM patients with renal dysfunction. Outcomes were similar to those of patients with preserved renal function. These findings support the use of BsAbs in this high‐risk population both in clinical practice and in future clinical trials.
- 2 April 2026
- Published by Wiley in American Journal of Hematology
- Vol. 101 (7) , 1484-1493
Open AccessThe Role of Bispecific Antibodies in Relapsed/Refractory Multiple Myeloma With Renal Impairment: A Systematic Review
Renal impairment (RI), defined as estimated glomerular filtration rate less than 60 mL/min with or without the need for dialysis, is a frequent and severe complication in patients with relapsed/refractory multiple myeloma (RRMM), as it can affect patient prognosis, drug metabolism and treatment options. Although bispecific antibodies (BsAbs) have been approved in RRMM patients, their safety and efficacy in patients with RI remain insufficiently characterized, as most clinical trials excluded individuals with significant renal dysfunction. This systematic review was conducted in accordance with the PRISMA guidelines. PubMed, Scopus, and ScienceDirect were searched up to February 2, 2026, for clinical trials and retrospective real‐world studies evaluating BsAbs in RRMM patients with reported data from patients with RI. Abstracts presented in major international scientific congresses over the preceding 3 years, including ASH, IMS, ASCO, EHA, EMN, were also systematically screened. A total of 11 eligible studies were identified, including 3 pivotal trials and 8 real‐world cohorts, encompassing 1117 patients. ORR, PFS and OS were comparable between patients with and without RI. Safety profile, including incidence of cytokine release syndrome (CRS), immune effector cell‐associated neurotoxicity (ICANS), infections and hematologic toxicities were also comparable across renal subgroups. Only the incidence of thrombocytopenia was significantly increased in patients with RI. Overall, BsAbs demonstrate substantial efficacy and manageable safety in RRMM patients with renal dysfunction. Outcomes were similar to those of patients with preserved renal function. These findings support the use of BsAbs in this high‐risk population both in clinical practice and in future clinical trials.
- 30 October 2025
- Published by ALUNA in Wiadomości Lekarskie
- Vol. 78 (10) , 2160-2166
Rabies: Known and Unknown Historical Aspects
Aim: to provide a comprehensive historical overview of rabies, with a focus on its early recognition, cultural significance, and advancements in treatment from antiquity to the modern era. Special emphasis is placed on the discovery of the rabies virus and the development of the first vaccine in 1885 by Louis Pasteur and Émile Roux. Materials and Methods: A literature review was conducted using electronic databases such as Scopus and PubMed to gather data on rabies incidence, transmission patterns, and public health interventions across various Latin American countries. In addition, supplementary searches were carried out in university and public libraries to obtain historical sources and regional data not readily available in digital repositories. Conclusions: Although significant progress has been made in reducing rabies cases in Latin America through widespread vaccination campaigns and animal control strategies, the disease continues to pose a public health concern in certain areas. This persistence is particularly attributed to challenges in rural and remote regions, bat-mediated transmission, and deficiencies in disease surveillance. Continued investment in preventive measures, public education, and targeted interventions—especially among vulnerable populations—is crucial for achieving the complete elimination of rabies in the region.
- 30 October 2025
- Published by ALUNA in Wiadomości Lekarskie
- Vol. 78 (10) , 2160-2166
Rabies: Known and Unknown Historical Aspects
Aim: to provide a comprehensive historical overview of rabies, with a focus on its early recognition, cultural significance, and advancements in treatment from antiquity to the modern era. Special emphasis is placed on the discovery of the rabies virus and the development of the first vaccine in 1885 by Louis Pasteur and Émile Roux. Materials and Methods: A literature review was conducted using electronic databases such as Scopus and PubMed to gather data on rabies incidence, transmission patterns, and public health interventions across various Latin American countries. In addition, supplementary searches were carried out in university and public libraries to obtain historical sources and regional data not readily available in digital repositories. Conclusions: Although significant progress has been made in reducing rabies cases in Latin America through widespread vaccination campaigns and animal control strategies, the disease continues to pose a public health concern in certain areas. This persistence is particularly attributed to challenges in rural and remote regions, bat-mediated transmission, and deficiencies in disease surveillance. Continued investment in preventive measures, public education, and targeted interventions—especially among vulnerable populations—is crucial for achieving the complete elimination of rabies in the region.
- 13 October 2025
- Published by Taylor & Francis in Leukemia & Lymphoma
- Vol. 66 (14) , 2774-2777
Remission of recurrent systemic capillary leak syndrome associated with monoclonal gammopathy following anti-myeloma treatment – a case report and literature review
- 13 October 2025
- Published by Taylor & Francis in Leukemia & Lymphoma
- Vol. 66 (14) , 2774-2777
Remission of recurrent systemic capillary leak syndrome associated with monoclonal gammopathy following anti-myeloma treatment – a case report and literature review